Valganciclovir is not a risk factor of BK polyomavirus viremia

Jehn, U.; Schütte‐Nütgen, Katharina; Bautz, Joachim; Suwelack, Barbara; Reuter, Stefan

doi:10.1111/ajt.15610

Cited by 5 publications

(12 citation statements)

References 5 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, there is data suggesting that BK viremia is related to valganciclovir prophylaxis [29]. However, we could not observe this association [30].…”

Section: Discussioncontrasting

confidence: 75%

Cytomegalovirus Viremia after Living and Deceased Donation in Kidney Transplantation

Jehn

Schütte‐Nütgen

Bautz

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

Despite screening, effective anti-viral drugs and risk-balanced prophylaxis, cytomegalovirus (CMV) remains a major cause of morbidity in transplant patients. The objective of this study was to retrospectively analyze the risk factors associated with CMV viremia after kidney transplantation in a large European cohort with standardized valganciclovir prophylaxis in the present era. A special focus was placed on the comparison of living and postmortal donation. We conducted a longitudinal observational study involving 723 adult patients with a total of 3292 patient-years who were transplanted at our center between 2007 and 2015. Valganciclovir prophylaxis was administered over 100 days for CMV+ donors (D) or recipients (R), over 200 days for D+/R−, and none in D−/R−. A CMV+ donor, rejection episodes, and deceased donor transplantation were identified to be associated with increased incidences of CMV viremia. Although we did not find a reduced overall survival rate for patients with CMV viremia, it was associated with worse graft function. Since we observed a relevant number of CMV infections despite prescribing valganciclovir prophylaxis, a pre-emptive strategy in patients with (suspected) adherence restrictions could be favored. Our data can help transplant physicians educate their patients about their individual CMV risk and choose the most appropriate CMV treatment approach.

show abstract

“…Interestingly, there is data suggesting that BK viremia is related to valganciclovir prophylaxis [29]. However, we could not observe this association [30].…”

Section: Discussioncontrasting

confidence: 75%

Cytomegalovirus Viremia after Living and Deceased Donation in Kidney Transplantation

Jehn

Schütte‐Nütgen

Bautz

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…To our knowledge, there is however no scientific support for an effect in vitro nor in vivo of valganciclovir on HPyVs. Notably, however, prophylaxis with valganciclovir to kidney transplant recipients did not decrease HPyV viraemia nor development of polyoma‐associated nephropathy 71,72 . Reducing patient immunosuppression is effective but often unfeasible due to the risk of organ rejection or flaring of underlying disease.…”

Section: Treatmentmentioning

confidence: 99%

“…70 This holds true primarily for cidofovir and reduced immunosuppression, whereas, as previously mentioned, the mechanism of action for valganciclovir in HPyV infection remains unknown. 71 Further studies are warranted to elucidate the mechanistic bases for these treatments. A limitation of the conclusions reachable in this review is that it is impossible to firmly know whether the patients would have improved even without treatment, since many cases of TS show spontaneous regression over time.…”

Section: Treatmentmentioning

confidence: 99%

“…Notably, however, prophylaxis with valganciclovir to kidney transplant recipients did not decrease HPyV viraemia nor development of polyoma-associated nephropathy. 71,72 Reducing patient immunosuppression is effective but often unfeasible due to the risk of organ rejection or flaring of underlying disease. The majority of treatments display no or poor effect, including widely used topical treatments such as retinoids, glucocorticoids, keratolytics, imiquimod and antibiotics, and systemic treatments such as retinoids and antibiotics (Table 2).…”

Section: Treatmentmentioning

confidence: 99%

“…A common denominator for the treatments proven efficacious is that they reduce the causative agent, either by reducing the viral load of TSPyV by anti‐viral effect or by a reduction of immunosuppression 70 . This holds true primarily for cidofovir and reduced immunosuppression, whereas, as previously mentioned, the mechanism of action for valganciclovir in HPyV infection remains unknown 71 . Further studies are warranted to elucidate the mechanistic bases for these treatments.…”

Section: Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Trichodysplasia spinulosa: a comprehensive review of the disease and its treatment

Curman

Näsman

Brauner

2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

Trichodysplasia spinulosa (TS) is a rare dermatological disease caused by TS-associated polyomavirus (TSPyV) in immunosuppressed patients. The seroprevalence of TSPyV in immunocompetent adults is high and the number of immunosuppressed patients developing TS remains low, suggesting that TS is underdiagnosed and/or that additional unknown factors are needed in order to develop TS. There is no well-established treatment for TS, and to date a majority of reported cases have consequently received ineffective therapies, likely due to the unavailability of reviews and recommendations of treatments for TS. The few treatments reported in case reports to be effective include topical cidofovir 3%, reduction of immunosuppression and oral valganciclovir. In this comprehensive review, we present all published cases to date, together with a summary of all treatments for TS categorized by overall clinical efficacy, thus addressing this rare disease and what appears to be its clinically efficacious treatment.

show abstract

Is Polyomavirus-Associated Nephropathy More Common in Kidney Transplant Recipients Exposed to Valganciclovir? A Retrospective Single Center Analysis

Hellemans

Bertels

Wijtvliet

et al. 2023

Transplantation Proceedings

View full text Add to dashboard Cite

Valganciclovir is not a risk factor of BK polyomavirus viremia

Cited by 5 publications

References 5 publications

Cytomegalovirus Viremia after Living and Deceased Donation in Kidney Transplantation

Cytomegalovirus Viremia after Living and Deceased Donation in Kidney Transplantation

Trichodysplasia spinulosa: a comprehensive review of the disease and its treatment

Is Polyomavirus-Associated Nephropathy More Common in Kidney Transplant Recipients Exposed to Valganciclovir? A Retrospective Single Center Analysis

Contact Info

Product

Resources

About